CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Learn how to use compound interest in your retirement planning, ensuring a comfortable and financially secure future.
23,811 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
EU officials weigh a broader crackdown on Russia-linked crypto platforms, with non-EU services facing tighter curbs a...
Brazilian officials say May deforestation hit a record low, even as the U.S. weighs new tariffs. The so-called 'trump...
Insider moves always spark questions. This article unpacks EverCommerce's sells 19,200 shares, what it signals, and h...
David Cordani is stepping aside as Cigna's CEO to become executive chairman, ending a 17‑year run that propelled the ...
A looming funding crunch could threaten Ethereum’s roadmap within the next three to nine months. An ex-Ethereum Found...
Nscale raised billions to power Europe’s AI ambitions, but the company now confronts the need to prove it can transla...
Is DraftKings stock analysis signaling a sell or a hold? This deep dive breaks down how regulation, competition, and ...
Brent crude sits around $74 per barrel as of 8:45 a.m. ET on June 25, 2026, marking a quiet pause after recent volati...
Speculation over a Taylor Swift and Travis Kelce wedding at Madison Square Garden is fueling conversations about hote...
A routine stop at a Walmart in Michigan grew into a wider look at retail fraud across several counties. This article ...
A 740,000-vehicle recall casts a long shadow over Ford's rebound story, threatening brand trust and investor sentimen...